SCHEMBL21180310

SCHEMBL21180310

CC/C(C)=C/Cc1c(O)cc(C)cc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.63
BACE1 P56817 1/20 0.63
CYP19A1 P11511 1/20 0.45
PPARG P37231 6/20 0.43
CNR1 P21554 2/20 0.43
CNR2 P34972 2/20 0.43
TRPV1 Q8NER1 2/20 0.43
TRPA1 O75762 1/20 0.43
INHA P05111 1/20 0.43
SLC6A2 P23975 1/20 0.43
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
OPRM1 P35372 1/20 0.43
SLC6A3 Q01959 1/20 0.43
KCNH2 Q12809 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.43
TRPV3 Q8NET8 1/20 0.43
TRPV4 Q9HBA0 1/20 0.43
TRPV2 Q9Y5S1 1/20 0.43
MAOB P27338 7/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9788451 0.82 PTPN1 (0.69) PTPN1BACE1CYP19A1PPARGCNR1
SCHEMBL19846964 0.79 PTPN1 (0.97) PTPN1BACE1PPARGCNR1CNR2
SCHEMBL23522862 0.79 PTPN1 (0.97) PTPN1BACE1PPARGCNR1CNR2
Grifolin SCHEMBL8589594 0.78 PTPN1 (1.00) PTPN1BACE1PPARGCNR1CNR2
Grifolin SCHEMBL21065400 0.78 PTPN1 (1.00) PTPN1BACE1PPARGCNR1CNR2
SCHEMBL24804443 0.73 PTPN1 (0.58) PTPN1BACE1CYP19A1PPARGCNR1
SCHEMBL24805135 0.72 PTPN1 (0.83) PTPN1BACE1PPARGCNR1CNR2
SCHEMBL29115719 0.71 PTPN1 (0.47) PTPN1BACE1PPARGCNR1CNR2
SCHEMBL9901006 0.71 PTPN1 (0.47) PTPN1BACE1CYP19A1PPARGTRPA1
SCHEMBL14407273 0.71 IMPDH2 (0.42) MAOBAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
US-10377733-B1 Antimicrobials from an epigenetics based fungal metabolite screening program UNIVERSITY OF SOUTH FLORIDA (US) 2019-08-13 US disclosed
US-10358431-B1 Antimicrobials from an epigenetics based fungal metabolite screening program UNIVERSITY OF SOUTH FLORIDA (US) 2019-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10358431-B1 Antimicrobials from an epigenetics based fungal metabolite screening program HDAC7, HDAC9, HDAC4 PTPN1 4758/4885BACE1 3698/4885CYP19A1 3615/4885
US-10377733-B1 Antimicrobials from an epigenetics based fungal metabolite screening program HDAC7, HDAC9, HDAC4 PTPN1 4758/4885BACE1 3698/4885CYP19A1 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.